Clinical trials are essential to the development of effective treatments for chronic autoimmune arthritis. For ethical, practical, and financial reasons, researchers increasingly face the challenge of achieving proof-of-concept in early-phase clinical trials of limited size, limited duration, and minimal patient risk. Analysis of tissue from the synovium, the thin membrane lining the joint space and primary target of inflammation, provides a straightforward way to meet this challenge. This approach has been used extensively, and proven valuable, in studies of rheumatoid arthritis (RA).
Spondylarthritis (SpA) refers to a group of chronic autoimmune arthritic conditions, including ankylosing spondylitis (AS) and the arthritis associated with psoriasis and inflammatory bowel diseases, primarily affecting peripheral joints. For an international alliance of researchers, synovial tissue analysis presented an ideal vehicle for identifying biomarkers of SpA. Their findings, featured in the June 2006 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis), hold the promise to facilitate the progress of clinical trials dedicated to improving the treatment of SpA.
Led by Dr. Dominique Baeten at the University of Amsterdam's Academic Medical Center, the 12-week study included 52 patients who met established criteria for SpA. Patients were randomly divided into three groups. Two groups were treated with a tumor necrosis factor (TNF) blockade 20 received infliximab and 20 received etanercept. None of these 40 patients was being treated with a disease-modifying antirheumatic drug (DMARD). The remaining 12 patients served as controls. At the study's inception and again at its culmination, each patient participated in a thorough assessment of disease symptoms and pain.
At the same intervals, weeks 0
'"/>
Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
25-May-2006
Page: 1 2 3 Related medicine news :1.
Scientists create dual-modality microbeads to improve identification of disease biomarkers2.
Newer biomarkers add small improvement in cardiovascular risk prediction to established risk factors3.
Ability of biomarkers to predict risk of heart disease, stroke appears limited4.
Researchers use statistical technique to find mix of biomarkers predicting mortality5.
New microchip technology for medical imaging biomarkers of disease6.
National quality agenda, payment reform, care integration keys to improving quality, patient safety7.
HCV patients survival after liver transplantation is not improving8.
Major discovery raises prospect of better patient care by improving platelet life span9.
Options improving for patients with acromegaly and gigantism, says endocrinology expert10.
Interagency relations key to improving outcomes from UK health research11.
Balance training better than tai chi at improving mobility among older adults